Abstract-Human plasma platelet-activating factor acetylhydrolase (PAF-AH) is a phospholipase A 2 that is primarily associated with low density lipoprotein (LDL). PAF-AH activity has also been found in high density lipoprotein (HDL), although it has recently been indicated that there is no PAF-AH protein in HDL. Plasma paraoxonase 1 (PON1) is an HDL-associated esterase, which also exhibits PAF-AH-like activity. The effect of atorvastatin (20 mg per day for 4 months) on PAF-AH and PON1 activities in patients with dyslipidemia of type IIA (nϭ55) or type IIB (nϭ21) was studied. In both patient groups, atorvastatin significantly reduced plasma PAF-AH activity because of the decrease in LDL plasma levels and the preferential decrease in PAF-AH activity on dense LDL subfractions (LDL-4 and LDL-5). Drug therapy did not affect HDL-associated PAF-AH activity or serum PON1 activities toward paraoxon and phenylacetate in either patient group. However, because of the reduction in LDL cholesterol levels, the ratios of HDL-associated PAF-AH and serum PON1 activities to LDL cholesterol levels were significantly increased after drug administration. The reduction of the LDL-associated PAF-AH activity and the elevation in the ratios of HDL-associated PAF-AH and PON1 activities to LDL plasma levels may represent a new dimension in the antiatherogenic effect of atorvastatin. 
P latelet-activating factor (PAF) is a potent lipid mediator involved in inflammatory diseases 1 as well as in atherogenesis. 2 In plasma, PAF is hydrolyzed and inactivated by PAF-acetylhydrolase (PAF-AH, EC 3.1.1.47), a Ca 2ϩ -independent phospholipase A 2 . 3 PAF-AH has a marked preference for phospholipids with short-chain moieties at the sn-2 position, and with the exception of PAF, PAF-AH can equally hydrolyze oxidized phospholipids containing a polyunsaturated fatty acyl residue at this position. 3 Plasma PAF-AH is complexed to lipoproteins 4, 5 ; thus, it is also denoted as lipoprotein-associated phospholipase A 2 . 6 The role of this enzyme in inflammatory and atherosclerotic diseases remains to be established. Indeed, PAF-AH may represent a potent anti-inflammatory and antiatherogenic enzyme because it degrades PAF and proinflammatory oxidized phospholipids, molecules formed during the oxidation of LDL. 7 Consistent with the hypothesis that PAF-AH may exert a cardioprotective role are clinical studies showing that loss of plasma PAF-AH activity due to a G9943 T mutation in the PAF-AH gene may constitute a genetic determinant of atherosclerotic disease in the Japanese population. 8 In contrast to these findings, PAF-AH may exert proinflammatory and proatherogenic actions as a result of the hydrolysis of oxidized phospholipids, because bioactive oxidized free fatty acids 6 and lysophosphatidylcholine are generated. 9, 10 A recent clinical study indicating that the mass of plasma PAF-AH could be a potential risk factor for coronary artery disease is consistent with the latter observations. 11 Human plasma paraoxonase 1 (PON1) is an esterase that is present in plasma in association with HDL. 12 In vitro, PON1 hydrolyzes paraoxon and phenylacetate; by contrast, the in vivo substrates for this enzyme are considered to be phospholipid hydroperoxides and cholesteryl ester hydroperoxides, molecules that are formed during LDL oxidation. 13 Recently, it has been shown that PON1 hydrolyses PAF, thus exhibiting PAF-AH-like activity. 14 In this context, it has been further indicated that there is no PAF-AH protein in HDL, suggesting that the HDL-associated PAF-AH activity is due to PON1. 14 It has been shown that PON1 is able to retard LDL oxidation 15 and to reduce the proinflammatory effects of oxidized LDL. 16 Furthermore, PON1 may inhibit HDL oxidation, thereby preserving its antiatherogenic functions. 17 Clinical trials of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) demonstrate a significant reduction in cardiovascular morbidity and mortality that is incompletely explained by their LDL cholesterol-lowering effects. 18, 19 The beneficial effects of statins may also involve nonlipid mechanisms, including anti-inflammatory and antioxidative effects. 20, 21 In the present study, we investigated the effect of atorvastatin therapy on the circulating activities of PAF-AH and PON1 in patients with dyslipidemia of type IIA and type IIB. We also studied the drug effect on PAF-AH production and secretion by the patients' peripheral blood monocyte-derived macrophages in culture.
Methods Patients
Seventy-six unrelated hyperlipidemic patients attending the Lipid Clinic of the University Hospital of Ioannina participated in the present study. According to their lipid levels, patients were divided into the primary hypercholesterolemia (dyslipidemia type IIA) group (LDL cholesterol Ͼ160 mg/dL) and the combined hyperlipidemia (dyslipidemia type IIB) group (LDL cholesterol Ͼ160 mg/dL and triglycerides Ͼ200 mg/dL). Among dyslipidemic type IIA patients, 36 had a diagnosis of heterozygous familial hypercholesterolemia (FH), and 19 had a diagnosis of polygenic hypercholesterolemia (NonFH). Atorvastatin treatment was initiated in all patients at a single dose of 20 mg at bedtime for 4 months; then a second blood analysis was performed after a 14-hour overnight fast. For comparison of PAF-AH and PON1 activities between patient groups and normolipidemic subjects, 45 apparently healthy normolipidemic individuals receiving no medication served as control subjects. For supplementary online material involving patient selection criteria and patient characteristics, please see the text and Table I at http://www.atvb.ahajournals.org.
Subfractionation of Plasma Lipoproteins
Lipoproteins were fractionated by isopycnic density gradient ultracentrifugation into the following subfractions: VLDLϩIDL, density (d)Ͻ1.019 g/mL; LDL-1, dϭ1.019 to 1.023 g/mL; LDL-2, dϭ1.023 to 1.029 g/mL; LDL-3, dϭ1.029 to 1.039 g/mL; LDL-4, dϭ1.039 to 1.050 g/mL; LDL-5, dϭ1.050 to 1.063 g/mL; HDL-2, dϭ1.063 to 1.100 g/mL; HDL-3, dϭ1.100 to 1.167 g/mL; and VHDL, dϭ1.167 to 1.190 g/mL. For more details on lipoprotein subfractionation, please see http://www.atvb.ahajournals.org.
Isolation and Culture of Human Blood Monocytes
Peripheral blood from patients (before the initiation of therapy with atorvastatin) and from healthy volunteers was drawn into EDTAcontaining tubes. Blood was centrifuged, and monocytes were isolated from the buffy coats as previously described. 22 For more details on cell culture conditions, please see http://www.atvb.ahajournals.org.
RNA Isolation, First-Strand cDNA Synthesis, and Reverse Transcription-Polymerase Chain Reaction
Total RNA was isolated with RNA Plus (Q-B10 gene) from adherent macrophages before and 48 hours after atorvastatin treatment. Detection and quantification of PAF-AH mRNA was performed by reverse transcription-polymerase chain reaction. 22 For more details, please see http://www.atvb.ahajournals.org. 
Measurement of PAF-AH and PON1 Activities

Analytical Methods and Statistical Analysis
For analytical methods and statistical analysis, please see online supplement at http://www.atvb.ahajournals.org.
Results
Effect of Atorvastatin Therapy on Plasma Lipid Profile
As expected, atorvastatin significantly decreased serum total cholesterol and LDL cholesterol levels as well as serum apoB and apoE levels in both patient groups. A significant reduction in serum triglycerides in both groups was equally observed; the reduction was more profound in dyslipidemic type IIB patients (see online Table II at http://www.atvb.ahajournals.org).
Plasma PAF-AH Activity
As shown in the Table, total plasma PAF-AH activity at baseline was higher in both patient groups compared with the control group (PϽ0.0001 for both comparisons). Furthermore, baseline enzyme activity in type IIB patients was significantly lower than that in type IIA patients (PϽ0.01). When the primary hypercholesterolemia group was subdivided into FH and NonFH patients, the enzyme activity in FH patients (95.7Ϯ30.5 nmol/mL per minute) was significantly higher than that in NonFH patients (70.0Ϯ15.2 nmol/mL per minute, PϽ0.004). No difference in the HDL-associated PAF-AH activity (HDL-PAF-AH), expressed per milliliter of plasma, was observed between type IIA patients and control subjects, whereas compared with either control subjects or type IIA patients, type IIB patients exhibited lower HDL-PAF-AH (PϽ0.002 for both comparisons, Table) . Furthermore, when type IIA patients were subdivided into FH and NonFH, no differences were observed in the HDL-associated enzyme activity (data not shown). It is important to note that the ratio of HDL-PAF-AH to LDL cholesterol levels (expressed as nanomoles per milligram LDL cholesterol per minute) was significantly lower in both patient groups compared with the control group (PϽ0.0001 for both comparisons), whereas no difference in this ratio was observed between the patient groups (Table) .
Interestingly, atorvastatin treatment led to a reduction in plasma PAF-AH activity in both patient groups (Table) . Enzyme activity in type IIB patients was decreased by 42.4% to reach control values (PϽ0.001). A decrease in enzyme activity (Ϫ28.6%, PϽ0.001) was also observed in type IIA patients; however, in this patient group, enzyme activity remained significantly elevated compared with that in the control group even after atorvastatin therapy (Table) . This phenomenon was due to the enzyme activity in FH patients, which remained elevated compared with enzyme activity in the control subjects (69.1Ϯ22.7 versus 43.8Ϯ13.0 nmol/mL per minute, respectively; PϽ0.04), whereas the posttreatment values in the NonFH patients (48.4Ϯ12.9 nmol/mL per minute) were similar to those in the control group. The reduction of enzyme activity was significantly correlated with the decrease in plasma LDL cholesterol levels ( Figure 1) .
In contrast to total plasma enzyme activity, atorvastatin therapy did not affect HDL-PAF-AH activity in either patient group (Table) . Consequently, the ratio of HDL-PAF-AH to LDL cholesterol levels was significantly increased in both groups (31% in type IIA patients and 91% in type IIB patients, PϽ0.0002 for both comparisons; Table) . Similar results were obtained when HDL-PAF-AH was expressed per LDL mass or apoB plasma levels (data not shown). Despite the significant increase in the above ratio after atorvastatin therapy, it remained lower in both patient groups compared with the control group (Table) .
Serum PON1 Activity
Serum PON1 activity toward paraoxon was lower (although not statistically significant) in the type IIA patients than in the control subjects (Table) . When this group was subdivided into FH and NonFH patients, the enzyme activity in FH group (67.7Ϯ36.1 U/L) was lower than that in the control group (89.9Ϯ44.5 U/L) and in the NonFH group (89.2Ϯ54.8 U/L, PϽ0.04 for both comparisons), a finding that is in agreement with previous results. 21, 23 No difference in PON1 activity toward paraoxon was observed between control subjects and type IIB patients. Unlike PON1 activity toward paraoxon, the baseline values of PON1 activity toward phenylacetate were significantly lower in both patient groups compared with the control group (Table) . It is important to note that atorvastatin did not affect either of the PON1 activities in the patient groups. However, because of the reduction in LDL cholesterol levels, the ratio of both PON1 activities to LDL cholesterol levels (in units per milligram LDL cholesterol) was significantly increased after drug administration, although it remained lower than the corresponding control values (Table) . The same results were obtained when both PON1 activities were expressed per LDL mass or apoB plasma levels (data not shown).
Effect of Atorvastatin on the Mass Distribution of Plasma Lipoprotein Subspecies
To further investigate the effect of atorvastatin on the PAF-AH activity associated with individual lipoprotein subclasses, we fractionated plasma lipoproteins in each patient before and after atorvastatin therapy. As shown in online Table III (please see http://www.atvb.ahajournals.org), atorvastatin therapy in type IIA patients significantly reduced the mass of the VLDLϩIDL subfraction (Ϫ39.2%) and total LDL (Ϫ26.3%). The reduction in total LDL mass was mainly due to a reduction of large and intermediate LDL subspecies (ie, LDL-1 to LDL-3), whereas no significant change was observed in the dense subfractions LDL-4 and LDL-5. Atorvastatin therapy in type IIB patients led to equally significant reductions of VLDLϩIDL mass (Ϫ47.9%) and total LDL mass (Ϫ32.7%). The reduction in total LDL mass was due to a reduction in all LDL subspecies (LDL-1 to LDL-5). Finally, no significant alterations were observed in total HDL mass or in the mass of individual HDL subspecies after atorvastatin treatment in both patient groups (please see online Table III ). 
Effect of Atorvastatin on Plasma PAF-AH and PON1 Activities in Control Subjects and in Patients With
PAF-AH Activity in Plasma Lipoprotein Subspecies
PAF-AH activity was determined in all apoB-containing and apoA-I-containing plasma lipoprotein subspecies. The enzyme activity, expressed per milligram of protein, per milligram of lipoprotein mass, or per milliliters of plasma, was preferentially associated with the dense LDL-5 subfraction in both patient groups. Figure 2 illustrates the results of PAF-AH activity expressed per milligram of protein. There were no significant differences in enzyme activity in each subfraction between the 2 groups. However, compared with the control group, both patient groups exhibited significantly higher enzyme activity associated with VLDLϩIDL, LDL-1, LDL-2, and LDL-5 subfractions (Figure 2 ). Atorvastatin significantly reduced the total enzyme activity (expressed per milliliter of plasma) associated with the VLDLϩIDL subfraction as well as with each LDL subfraction in both patient groups. Remarkably, a significant reduction was also observed in the enzyme activity (expressed either per milligram of protein or per milligram of lipoprotein mass) in the dense LDL subfractions (ie, LDL-4 and LDL-5); this phenomenon was not observed in the other apoB-containing lipoprotein subfractions. Figure 3 illustrates the PAF-AH activity in these subfractions, expressed per milligram of protein. Finally, no changes were observed in the enzyme activity associated with each HDL subfraction after atorvastatin therapy in either patient group.
Effect of Atorvastatin on PAF-AH Secretion From Macrophages
It has been shown that macrophages represent the major source of the plasma-and LDL-associated PAF-AH activity. 24 To investigate whether the reduction in plasma-and LDL-associated PAF-AH activity by atorvastatin was due to any drug effect on enzyme secretion, we studied the effect of atorvastatin on PAF-AH production and secretion by peripheral blood monocyte-derived macrophages. Cells isolated from 8 subjects of each group were used in these studies. Incubations were performed for 24 and 48 hours with various concentrations of atorvastatin, ranging from 0.005 to 10 mol/L. There was a steady increase in total (secreted plus cell-associated) PAF-AH activity in untreated cells (incubated with dimethyl sulfoxide in the absence of atorvastatin) from normolipidemic control subjects, attaining 244Ϯ66 nmol/mg DNA per hour at 24 hours of culture and 494Ϯ97 nmol/mg DNA per hour at 48 hours of culture. This increase reflected mainly the secreted enzyme activity, which was 146Ϯ32 nmol/mg DNA per hour (60% of total) at 24 hours of culture and 395Ϯ73 nmol/mg DNA per hour (80% of total) at 48 hours of culture. Similar results were obtained for untreated macrophages from both patient groups (data not shown). Cell treatment with atorvastatin at low doses (0.005 and 0.05 mol/L) for 48 hours significantly increased the secreted enzyme activity to a similar extent in all studied groups (Figure 4) , whereas a slight but not significant increase from 98.8Ϯ26 nmol/mg DNA per hour to 110Ϯ38 and 117Ϯ41 nmol/mg DNA per hour (at 0.005 and 0.05 mol/L atorvastatin, respectively) in the cell-associated enzyme activity was also observed in all studied groups. Overall, compared with no treatment, atorvastatin treatment significantly increased the total enzyme activity by 33Ϯ8% in all studied groups (PϽ0.01). Surprisingly, this phenomenon was not observed at higher atorvastatin doses (up to 10 mol/L). It must be noted that in enzyme assays performed in the presence of 0.005 to 10 mol/L atorvastatin with the use Figure 2 . PAF-AH activity in all apoB-containing lipoprotein subfractions of patients with dyslipidemia type IIA and type IIB before atorvastatin therapy and of normolipidemic control subjects. Plasma lipoproteins were subfractionated by isopycnic gradient ultracentrifugation, and enzyme activity was determined by the TCA precipitation procedure. Values are meanϮSD. *PϽ0.05 compared with control group. of macrophage supernatant as the source of the enzyme (containing 7.8 nmol/mL per minute of PAF-AH activity), no effect of the drug on PAF-AH activity was observed. To investigate whether the increase in PAF-AH activity induced by low doses of atorvastatin was due to an increase in the enzyme expression, we evaluated the PAF-AH mRNA levels. No differences were observed in the enzyme expression between untreated and atorvastatin-treated cells in all group studied (data not shown), suggesting that the increase in PAF-AH production and secretion induced by atorvastatin is due to a drug effect at the posttranscriptional level.
Discussion
In the present study, we show for the first time that atorvastatin therapy in patients with primary hypercholesterolemia as well as in those with combined hyperlipidemia significantly reduces total plasma PAF-AH activity. This phenomenon is due to not only a reduction in plasma LDL levels but also a decrease in the enzyme activity associated with the dense LDL subspecies. Atorvastatin therapy did not affect HDL-PAF-AH activity, nor did it affect total serum PON1 activities toward paraoxon and phenylacetate in either patient group.
The higher plasma PAF-AH activity observed in type IIA patients, compared with control subjects, is in accordance with our published results. 9 In addition, our data reveal that compared with control subjects, type IIB patients exhibit significantly higher plasma enzyme activity. Consistent with our previous studies on normolipidemic and hypercholesterolemic subjects, 5,9 the majority of LDL-associated PAF-AH activity in both patient groups was associated with the dense LDL subfractions.
Atorvastatin therapy significantly reduced plasma PAF-AH activity in both patient groups. A similar effect was observed for lovastatin therapy in patients with non-insulindependent diabetes mellitus and in obese individuals 25 as well as in hypercholesterolemic patients. 26 The present study shows for the first time that atorvastatin reduces plasma PAF-AH activity by decreasing the LDL-associated enzyme, which has been recently shown to be a potential risk factor for coronary artery disease. 11 Indeed, plasma levels of PAF-AH activity mainly reflect LDL-associated enzyme activity. 4 The reduction in enzyme activity by atorvastatin could be due to either a decrease in PAF-AH secretion from its main cellular sources or the drug-induced enhancement of LDL clearance from plasma. 27 According to our results, atorvastatin did not reduce PAF-AH secretion from macrophages; thus, the decrease in plasma PAF-AH cannot be attributed to a reduction in enzyme secretion by this drug. Consequently, the enhancement in the rate of LDL removal from the circulation may represent the main mechanism by which atorvastatin reduces plasma PAF-AH activity. This is also supported by the positive correlation observed between the reduction of plasma LDL cholesterol levels and that of plasma PAF-AH activity. However, the decrease in plasma LDL may not represent the sole mechanism by which atorvastatin reduces the plasma PAF-AH activity. Indeed, the decrease of plasma LDL cholesterol levels in type IIA patients is due to the reduction in large and intermediate LDL subspecies (LDL-1 to LDL-3), ie, particles that are poor in PAF-AH activity. By contrast, atorvastatin does not affect the plasma levels of PAF-AH-rich dense LDL particles, whereas it significantly reduces the enzyme activity associated with these particles. Consequently, the decrease of plasma PAF-AH activity in this patient group is due to not only the reduction in the cholesterol-rich LDL particles but also the decrease in the enzyme activity associated with the dense LDL particles. This phenomenon may also contribute to the decrease in total plasma PAF-AH activity (observed in type IIB patients) in which the reduction of plasma LDL concerns all LDL subspecies.
PAF-AH activity can be influenced by alterations in the lipid composition of the lipoproteins. 28 We excluded the possibility that the reduction in the enzyme activity on LDL-4 and LDL-5 induced by atorvastatin could be due to alterations in their lipid composition, because no major alteration in the chemical composition of any LDL subfraction was observed after drug therapy (data not shown). It has been reported that apoB conformation is distinct among LDL subspecies 29 and that apoB (and especially its carboxyl terminus) plays a key role in the association of PAF-AH with LDL. 30 Thus, a differential effect of atorvastatin on the interaction of PAF-AH with the apoB moiety of LDL subspecies, which might result in a specific reduction in enzyme activity on LDL-4 and LDL-5, cannot be excluded.
Unlike total plasma-and LDL-associated PAF-AH, there is a paucity of data on the plasma levels of HDL-associated PAF-AH activity in atherosclerotic diseases. According to our results, the ratio of HDL-PAF-AH to LDL cholesterol levels was significantly lower in both patient groups compared with the control group. This observation is consistent with our published data on FH patients 9 as well as with data on patients with unstable angina. 31 Several lines of evidence suggest that HDL protects LDL against oxidation and inhibits the biological activity of oxidized LDL. These effects are at least partially mediated by the HDL-associated PAF-AH activity. 32 The antiatherogenic role of HDL-PAF-AH is further supported by recent studies in apoE-deficient mice. 33, 34 Besides PAF-AH, 2 other HDL-associated enzymes, lecithin-cholesterol acyltransferase 35 and PON1, 14 exhibit PAF-AH-like activity; thus, the HDL-associated PAF-AH activity may represent a pool of similar catalytic activities expressed by 3 different enzymes. In this context, it has recently been shown that there is no PAF-AH protein in HDL, suggesting that the PAF-AH protein may not contribute to the HDL-associated PAF-AH activity. 14 Atorvastatin therapy affected neither total plasma HDL cholesterol levels nor HDL-PAF-AH activity. Consequently, it significantly increased the ratios of HDL-PAF-AH to LDL cholesterol levels because of a decrease in the LDL cholesterol levels. Similarly, atorvastatin affected neither PON1 activity toward paraoxon nor PON1 activity toward phenyl acetate. However, because of the decrease in plasma LDL cholesterol levels, a significant increase in the ratios of both PON1 activities to LDL cholesterol levels was observed. Thus, atorvastatin may exert a beneficial antioxidant and antiatherogenic effect by improving the HDL potency against LDL oxidation and against the atherogenic biological effects of oxidized LDL.
In conclusion, atorvastatin therapy in dyslipidemic type IIA and type IIB patients significantly decreases LDLassociated PAF-AH activity. This effect along with the improvement in the ratios of HDL-associated PAF-AH and
